Month: July 2017

If you are interested in being part of the Canadian Cancer Survivor Network’s All-Party Cancer Caucuses at the Ontario legislature in Toronto or the Alberta legislature in Edmonton, there is still time to join! The objectives of the two All-Party Cancer Caucuses are to: Bring together MPPs/MLAs from all parties, CCSN and patient and caregiver representatives two to three times a year to discuss issues

The Canadian Cancer Action Network (CCAN), in collaboration with CADTH, are pleased to announce that they are launching an enhanced Cancer Drug Information Pipeline for Patient Groups by transitioning it to a more advanced, user-friendly format with a search engine platform. This new search engine database was co-developed by CCAN and the CADTH pan-Canadian Oncology Drug Review (pCODR) program, with input from CCAN’s pan-Canadian Health Technology

Have you been diagnosed with head and neck cancer and want to get more involved in the cancer community? CCSN has several advisory councils, and we’re now starting a new one on head and neck cancer. Our advisory councils are a great way for patients, survivors, caregivers or family members to participate in projects and activities to improve cancer diagnosis, treatment and survivorship. Members of

The Canadian Cancer Action Network, in partnership with Carers Canada and the Canadian Home Care Association, is pleased to publically launch the 2017 report, Advancing Collective Priorities: A Canadian Carer Strategy today. Over 8 million carers (also referred to as family caregivers) impact the lives of Canadians every day. Providing care and support to loved ones, family members and friends, they contribute over $25 billion

New criteria for the following products have been added to the Newfoundland and Labrador Prescription Drug Program (NLPDP) Benefit List effective June 1, 2017. Special Authorization New Addition The following was reviewed by the pan Canadian Oncology Drug Review (pCODR) recommended for coverage with criteria: COTELLIC (Cobimetinib) 20mg DIN 02452340 In combination with vemurafenib, for the treatment of patients with previously untreated BRAF V600 mutation-positive

A research ethics board (REB) is a body of researchers, community members and others that is established to review the ethical acceptability of research involving humans. Working within a defined regulatory and ethical framework, the REB’s role is to safeguard the rights and welfare of the individuals who volunteer to participate in research. The composition of the REB and its collective expertise in ethical and